Revolutionising
Immunological Medicine

NLRP3 inflammasome, a pillar of personalised medicine in the fight against sepsis

fpunded-eurpe

EIC Transition (abril 2025)

Horizon Europe 2020-2027

Revolutionising the prognosis and early stratification of Sepsis

Anticipation saves lives: Identifying risk before it becomes critical

More information

VIVA-ELISA®, a pioneering anti-sepsis product for medical professionals

The first test that predicts the severity of sepsis before it becomes critical

More information

The Innovation route to market

VIVA-ELISA®: A scientific journey designed to save lives

More information

Objetive: United against sepsis

Reducing mortality in sepsis

Transforming the global sepsis landscape: faster screening, smarter treatment, outcomes with a direct impact on people's health and lives. 50% of cases are diagnosed too late.

Objetive: United against sepsis

The figures of a GLOBAL crisis

More than 49 million cases per year worldwide, with 3.4 million in Europe. And a shocking figure: 13.7 million globally, of which 680,000 occur in Europe.

Objetive: United against sepsis

With side effects: occupational sequelae

47-49% of patients are unable to return to work or return to work under the same conditions.

Objetive: United against sepsis

With a stifling economic impact on the EU

More than €28.4 billion annually, representing 2.65% of total EU healthcare expenditure, with an average patient cost per sepsis of €36,191, accounting for 47-49% of unemployed post-sepsis patients.

Our impact objetives

For patients

  • Reduce mortality by 25-40% through early screening
  • Reduce chronic after-effects
  • Shorten recovery

For hospitals

  • Reduce ICU stays
  • Lower costs per patient
  • Optimising resources with accurate triage

For health systems

  • Cost savings
  • Recover working hours/year for patient reintegration

Ongoing clinical validation

Bringing laboratory science into medical practice: results that save lives. 

Our technology has been validated with 158 patients and we have already initiated a pre-clinical evaluation with over 360 patients at leading hospitals and research centres across Spain. 

More information about our clinical trial
servicio-murciano-salud
sistemaandaluzsalud
arrixaca
hospital-virgen-victoria
hospital-jerez
Logos-imib-1.png
ibima
inibica-1.jpeg

We hold international patent (PCT) WO 2020/182964 A1, and have published national phases in the European Union, Israel, Canada and the United States.

Implementation of Blockchain platform and implementation of ISO 13485 quality system.

Regulatory Roapmap for market access, with EU (IVDR) Class C, and USA (FDA), Class II, 510K.

Haz clic aquí

Bussines Acceleration Programm

We are part of Business Acceleration Services (BAS), one of the largest programmes of business acceleration services supporting the growth of new disruptive technologies. BAS helps transform innovative ideas into solid business ventures by providing access to specialised business services, mentoring, and opportunities to secure contracts with institutions, corporations and private companies, etc.

Find out more

News

See all news

Join the cutting edge of biomedical research

Subscribe to VIVA Insights: The leading newsletter on inflammasomes and sepsis 

Receive exclusive analysis, scientific breakthroughs and collaboration opportunities from our network of international partners and benchmarks.

funded-europe
  • Murcia Science Park, Building T, 1st Floor (Module T1/3). Ctra. Madrid km. 388 30100 Murcia
  • +34 601 995 952
  • info@vivaivd.com
Linkedin
Esta web está diseñada y programada por Pantumaka Comunicación. Agencia de publicidad y marketing digital en Murcia.
Revolutionising the prognosis and early stratification of Sepsis

Our research in sepsis has led us to develop VIVA-ELISA® , an advanced diagnostic technology, based on the activation of the NLRP3 inflammasome by detecting ASC-Speck, which allows early identification and screening of critically ill septic patients in a simpler and faster way.  

Pioneering innovation for medical professionals, research companies and health services to deliver personalised treatments and reduce mortality. 

IN SEPSIS, THE COUNTDOWN IS ALWAYS AGAINST THE CLOCK
  • Every hour of diagnosis delay increases mortality by 7.6% 
  • 50% of cases are identified too late for effective interventions 
  • Hospital cost: 36,191€ average cost per septic patient.


International Recognition: We are one of the 40 European companies selected for the prestigious EIC Transition programme (April 2025), within Horizon Europe 2020-2027. 
VIVA-ELISA®, a pioneering anti-sepsis product for medical professionals.

A pioneering solution for hospitals, health systems and the pharmaceutical industry, based on the detection of NLRP3 inflammasome activation using ASC-Specks. 

The current problem

Traditional diagnostic methods fail where they are most needed:

  • They do not assess the patient’s immune status. 
  • Critical delays – Results in hours when every minute counts.
The VIVA-ELISA® solution

There is an urgent need for effective solutions that can stratify patients, particularly those where the risk of complications and mortality is highest. That’s exactly what our technology (and our first solution in development) is designed to do: transform how sepsis is diagnosed and treated. 

    • Rapid, Simple and Accurate Diagnosis: Detection of immunological deterioration in critically ill patients, compatible with existing protocols and clinical guidelines.
    • Personalised Medicine: Enables treatment strategies tailored to NLRP3 inflammasome activation(proprietary patent).
    • Reduction of Complications and Mortality: Optimises medical decision-making in emergency situations.
    • Expansion into other Medical Areas: Our solutions have the potential to be applied across a broad range of conditions, including cardiovascular and neurodegenerative diseases, diabetes, cancer, and a wide spectrum of other inflammatory disorders.

The Innovation route to market

VIVA-ELISA®, with a maturity level of TRL4 (laboratory technology validation), marks a turning point in the industry.  

This project is driven by a team of experienced leaders and scientific researchers with international expertise, enabling us to develop a functional solution at TRL 6 (technology demonstrated and validated in a relevant environment), with plans for a market launch in the near future. 

Our goal is to transfer this validation to the clinical setting, ensuring its effectiveness and applicability in hospitals and research centres.